Cite
HARVARD Citation
Jones, J. et al. (n.d.). Patients with chronic lymphocytic leukemia with high-risk genomic features have inferior outcome on successive Cancer and Leukemia Group B trials with alemtuzumab consolidation: subgroup analysis from CALGB 19901 and CALGB 10101. Leukemia & lymphoma. 54 (12), pp. 2654-2659. [Online].